Results: DS-2969b was safe and well-tolerated up to and including the dose of 400 mg. Adverse events were nearly all mild and not drug-related, except for constipation, abdominal bloating, abdominal pain, and diarrhea observed as mild and drug-related in 4 respective subjects given DS-2969b. Systemic exposure was less than dosedependent and accumulation increased with the dose up to 31%. Plasma half-life was about 15 h. The major elimination route was urinary excretion. More than two log 10 CFU reduction was observed in two bacterial groups in the intestinal flora, i.e., the Clostridium coccoides and the Bifidobacterium groups. No reduction was observed in other groups. Since C. difficile shows higher in-vitro susceptibility to DS-2969b than these two groups, DS-2969b administration seems to have attained at all doses concentrations sufficient for the killing of C. difficile. Preserving the normal intestinal flora is important, as it may deter CDI recurrence.
Conclusion:
The results of the study support further development of DS-2969b.
Background:
We discovered DS-2969b, a novel oral DNA gyrase B inhibitor, for the treatment of Clostridium difficile infection (CDI), including the life-threatening infection due to the hyper-virulent NAP1/027 strain. DS-2969b showed dose-dependent efficacy in a hamster model of NAP1/027 infection, which was superior to vancomycin or fidaxomicin. DS-2969b proved safe and well tolerated in pre-clinical toxicology studies and in a first-in-human single ascending dose study in healthy subjects, which enabled conducting the multiple ascending dose study reported here to characterize its safety, pharmacokinetics, and effect on intestinal flora in healthy subjects over 14 days of daily administrations. Methods: Design: Investigator-blinded, sponsor-unblinded, placebo-controlled, randomized, single-center, sequential cohort study. Participants: 24 healthy male and female subjects (age 18 to 64) in three dose level cohorts of 8 each, randomized 6 to 2 active to placebo. Intervention: Daily oral administration of DS-2969b at the doses of 60, 200, and 400 mg or of placebo for 14 consecutive days. Results: DS-2969b was safe and well-tolerated up to and including the dose of 400 mg. Adverse events were nearly all mild and not drug-related, except for constipation, abdominal bloating, abdominal pain, and diarrhea observed as mild and drug-related in 4 respective subjects given DS-2969b. Systemic exposure was less than dosedependent and accumulation increased with the dose up to 31%. Plasma half-life was about 15 h. The major elimination route was urinary excretion. More than two log 10 CFU reduction was observed in two bacterial groups in the intestinal flora, i.e., the Clostridium coccoides and the Bifidobacterium groups. No reduction was observed in other groups. Since C. difficile shows higher in-vitro susceptibility to DS-2969b than these two groups, DS-2969b administration seems to have attained at all doses concentrations sufficient for the killing of C. difficile. Preserving the normal intestinal flora is important, as it may deter CDI recurrence.
Conclusion:
CDI remains a significant public health threat. Reuse of vancomycin is recommended for the treatment of 1-2 CDI recurrences, according to the Guidelines for Diagnosis, Treatment, and Prevention of CDI published by the American College of Gastroenterology, but quality of evidence is low. In case of ≥3 CDI recurrences, fecal microbiota transplant is recommended with modest quality of evidence and uncertainty around long-term outcome. Development of innovative anti-CDI antibiotics that have minimum impact on gut flora is necessary to reduce the rate of recurrence. We have developed DS-2969b for the purpose of CDI treatment. In preclinical studies, superior efficacy to vancomycin and fidaxomicin were observed. Safety and tolerability were initially confirmed in a first-in-human single ascending dose study. We have conducted the multiple ascending dose study reported here to characterize DS-2969b safety, pharmacokinetics, and pharmacological effects on the intestinal flora in healthy subjects.
Objectives
Primary Objectives  To assess the safety and tolerability of multiple oral doses of DS-2969b in healthy subjects  To assess the plasma PK of DS-2969a (free form of DS-2969b) after multiple oral doses of DS-2969b in healthy subjects Secondary Objective  To assess the fecal and renal elimination of DS-2969a after multiple oral doses of DS-2969b in healthy subjects 
Fecal levels of DS-2969a
Study days
Study schedule
Subjects were screened from Day -21 through Day -3, and were admitted to the clinical unit on Day -2 for baseline assessment. Fecal sample collection began from Check-in on Day -2 and continued until Check-out on Day 21. All the subjects provided a baseline fecal sample before treatment on Day 1 and were randomized to treatment. Blood/urine were also collected.
Results

Pharmacokinetics
Adverse Events
In preclinical studies, gut microbiome analysis showed antibacterial effect on one intestinal bacterial group at 10 µg/g of fecal level of DS-2969a. This is achievable in humans at 60 mg dose.
More than 2 log 10 CFU reduction was observed in two bacterial groups in the intestinal flora, i.e., the C. coccoides group and the Bifidobacterium group. CFU reduction in other groups was small.
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The bacterial DNA from fecal samples was extracted using the QIAamp DNA Stool Mini kit (Qiagen Sciences Inc.) with minor modifications. For determination of the bacterial counts in fecal samples, extracted DNA samples were used for qPCR to obtain the bacterial count.
